Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Congenital Cytomegalovirus: a "Now" Problem-No Really, Now.

Literature DB >> 27795304

Congenital Cytomegalovirus: a "Now" Problem-No Really, Now.

Abstract

Despite the clear need, progress toward a vaccine for congenital cytomegalovirus (CMV) has been slow. However, recent events have provided new interest, and several vaccine candidates are either in clinical trials or the trials are close to starting. In this issue of Clinical and Vaccine Immunology, Schleiss and colleagues show that a nonreplicating lymphocytic choriomeningitis virus (rLCMV)-vectored vaccine expressing CMV glycoprotein B (gB) and/or pp65 induces B and T cells and improves pup survival in a guinea pig model of congenital CMV infection (Clin Vaccine Immunol 24:e00300-16, 2017, https://doi.org/10.1128/CVI.00300-16). The combination vaccine appeared to be the most effective.

Entities: Disease Species

Keywords: CMV vaccine; congenital infections; cytomegalovirus; guinea pig

Mesh：

Substances：

Year: 2017 PMID： 27795304 PMCID： PMC5216425 DOI： 10.1128/CVI.00491-16

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

27 in total

1. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

Authors: David I Bernstein; Elizabeth A Reap; Kevin Katen; Aubrey Watson; Kaitlin Smith; Pamela Norberg; Robert A Olmsted; Amy Hoeper; John Morris; Sarah Negri; Maureen F Maughan; Jeffrey D Chulay
Journal: Vaccine Date: 2009-10-24 Impact factor: 3.641

2. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection.

Authors: K B Fowler; F P McCollister; A J Dahle; S Boppana; W J Britt; R F Pass
Journal: J Pediatr Date: 1997-04 Impact factor: 4.406

3. Does public perception of exposure risks and transmission mechanisms drive antiviral vaccine awareness? What if cytomegalovirus was transmitted by mosquitoes?

Authors: Mark R Schleiss
Journal: Curr Opin Virol Date: 2016-04-22 Impact factor: 7.090

4. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Authors: Elizabeth C Swanson; Pete Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Megan Schmit; Jason C Zabeli; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal: Vaccine Date: 2015-06-13 Impact factor: 3.641

5. Vaccine prevention of maternal cytomegalovirus infection.

Authors: Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal: N Engl J Med Date: 2009-03-19 Impact factor: 91.245

6. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.

Authors: David I Bernstein; Flor M Munoz; S Todd Callahan; Richard Rupp; Susan H Wootton; Kathryn M Edwards; Christine B Turley; Lawrence R Stanberry; Shital M Patel; Monica M Mcneal; Sylvie Pichon; Cyrille Amegashie; Abbie R Bellamy
Journal: Vaccine Date: 2015-12-02 Impact factor: 3.641

7. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.

Authors: Rhonda D Cardin; Fernando J Bravo; Derek A Pullum; Klaus Orlinger; Elizabeth M Watson; Andreas Aspoeck; Gerhard Fuhrmann; Farshad Guirakhoo; Thomas Monath; David I Bernstein
Journal: Vaccine Date: 2016-03-10 Impact factor: 3.641

8. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors: Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal: Vaccine Date: 2015-10-24 Impact factor: 3.641

9. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Authors: Mark R Schleiss; K Yeon Choi; Jodi Anderson; Janine Gessner Mash; Martine Wettendorff; Sally Mossman; Marc Van Damme
Journal: Vaccine Date: 2013-07-16 Impact factor: 3.641